ABBOTT LABORATORIES 8-K

What Happened
Abbott Laboratories announced on March 9, 2026 that it completed a public offering of $20,000,000,000 aggregate principal amount of senior notes across eight series to fund the proposed acquisition of Exact Sciences. The notes were sold under a pricing agreement dated February 23, 2026 and issued under the shelf prospectus and prospectus supplement filed in February 2026. Abbott says it will use the net proceeds, together with cash on hand and/or additional borrowings, to fund the Exact Sciences acquisition (per the Merger Agreement dated November 19, 2025), repay certain Exact Sciences indebtedness, pay related fees and expenses, and for general corporate purposes.

Key Details

• Total issued: $20.0 billion aggregate principal across eight series:
  • Floating Rate Notes due 2029: $1.0B
  • 3.700% Notes due 2029: $2.25B
  • 4.000% Notes due 2031: $2.5B
  • 4.300% Notes due 2033: $2.75B
  • 4.650% Notes due 2036: $3.75B
  • 4.750% Notes due 2038: $2.0B
  • 5.500% Notes due 2056: $3.75B
  • 5.600% Notes due 2066: $2.0B
• Underwriters/representatives included Morgan Stanley, Barclays, BofA Securities and J.P. Morgan Securities; offering documented in the February 23, 2026 Pricing Agreement and Prospectus Supplement.
• If the Exact Sciences Acquisition is not consummated by five business days after the later of February 17, 2027 (or any agreed extension), or if Abbott elects not to pursue the deal, Abbott must redeem the outstanding notes at 101% of principal plus accrued interest (special mandatory redemption).

Why It Matters
This debt offering provides the funding bridge for Abbott’s planned acquisition of Exact Sciences and may increase Abbott’s gross debt load in the near term while enabling the transaction and related repayments. The special mandatory redemption provision limits Abbott’s long-term exposure under these notes if the acquisition does not close (redemption at 101%). Investors should note the size, maturities and stated interest rates of the new notes, as they affect Abbott’s interest expense profile and debt maturity timeline; the company also discloses use of proceeds for acquisition-related payments and general corporate purposes.